Loading...
Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
Lien, Chia-En Kuo, Tsun-Yung Lin, Yi-Jiun Lian, Wei-Cheng Lin, Meei-Yun Liu, Luke Tzu-Chi Chou, Yu-Chi Chen, Charles
Lien, Chia-En
Kuo, Tsun-Yung
Lin, Yi-Jiun
Lian, Wei-Cheng
Lin, Meei-Yun
Liu, Luke Tzu-Chi
Chou, Yu-Chi
Chen, Charles
Citations
Altmetric:
Genre
Pre-print
Date
2021-03-22
Advisor
Committee member
Group
Department
Biology
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1101/2021.03.19.21254000
Abstract
Vaccination is currently the best weapon to control the COVID-19 pandemic. However, an alarming number of novel variants termed Variants of Concern (VoC) were found to harbor mutations that diminished the neutralizing capacity of antibodies elicited by the vaccines. We have investigated the neutralizing titers of antibodies from sera of humans and rats immunized with the MVC-COV1901 vaccine against pseudoviruses coated with the wildtype, D614G, B.1.1.7, or B.1.351 spike proteins. Rats vaccinated with two doses of adjuvanted S-2P retained neutralization activities against the B.1.351 variant, albeit with a slight reduction compared to wildtype. Phase 1 vaccinated subjects showed more reduced neutralization abilities against the B.1.351 variant. The study is among the first, to our knowledge, to demonstrate dose-dependent neutralizing responses against VoCs, particularly against B.1.351, from different doses of antigen in a clinical trial for a subunit protein COVID-19 vaccine. The appearance of vaccine escape variants is a growing concern facing many current COVID-19 vaccines and therapeutics. Strategies should be adopted against the ever-changing nature of these variants. The observations of this study grant us valuable insight into preemptive strikes against current and future variants.
Description
Citation
Citation to related work
medRxiv
Has part
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu